Literature DB >> 3472414

Acute promyelocytic leukemia.

E C Kingsley, B G Durie, H S Garewal.   

Abstract

Acute promyelocytic leukemia (APL) is a subtype of acute myelogenous leukemia frequently associated with disseminated intravascular coagulation (DIC). Data on 11 patients with APL treated at our institution were analyzed and compared with those of 147 published cases. Most had a bleeding diathesis at presentation and evidence of DIC eventually developed in all. Seven patients (64%) showed the t(15;17)(q22;q21) karyotype or a similar translocation. Using a chemotherapy induction regimen containing an anthracycline, complete remission, requiring a total of 14 courses of treatment, was achieved in six patients (55%). The median duration of response and median survival for complete responders were 10 and 15 months, respectively. Three patients (27%) died of bleeding complications during induction therapy. The tritiated-thymidine labeling index of leukemia cells predicted which patients would achieve a complete remission. Review of six studies of 147 patients with APL from the past 12 years supports the use of a chemotherapy induction regimen containing anthracycline or amsacrine and heparin for the treatment of DIC.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3472414      PMCID: PMC1307278     

Source DB:  PubMed          Journal:  West J Med        ISSN: 0093-0415


  17 in total

1.  High speed scintillation autoradiography.

Authors:  B G Durie; S E Salmon
Journal:  Science       Date:  1975-12-12       Impact factor: 47.728

2.  Heparin treatment for the hemorrhagic diathesis of acute promyelocytic leukemia.

Authors:  H R Gralnick; J Bagley; E Abrell
Journal:  Am J Med       Date:  1972-02       Impact factor: 4.965

3.  Acute promyelocytic leukemia: results of treatment by daunorubicin.

Authors:  J Bernard; M Weil; M Boiron; C Jacquillat; G Flandrin; M F Gemon
Journal:  Blood       Date:  1973-04       Impact factor: 22.113

4.  Acute promyelocytic leukemia. Management of the coagulopathy during daunorubicin-prednisone remission induction.

Authors:  A J Collins; C D Bloomfield; B A Peterson; R W McKenna; J R Edson
Journal:  Arch Intern Med       Date:  1978-11

5.  epsilon-Amino-caproic acid in the management of acute promyelocytic leukaemia.

Authors:  T J Keane; A M Gorman; L G O'Connell; J J Fennelly
Journal:  Acta Haematol       Date:  1976       Impact factor: 2.195

6.  Acute nonlymphocytic leukemia in adults: correlations with Q-banded chromosomes.

Authors:  H M Golomb; J Vardiman; J D Rowley
Journal:  Blood       Date:  1976-07       Impact factor: 22.113

7.  Acute promyelocytic leukemia: results of therapy and analysis of 13 cases.

Authors:  D Ruggero; M Baccarani; A Guarini; L Gugliotta; M Gobbi; P Ricci; A Zaccaria; F Lauria; I Tomasini; M Fiacchini; M A Santucci; S Tura
Journal:  Acta Haematol       Date:  1977       Impact factor: 2.195

8.  Prophylactic heparin therapy in acute promyelocytic leukemia.

Authors:  R L Drapkin; T S Gee; M D Dowling; Z Arlin; S McKenzie; S Kempin; B Clarkson
Journal:  Cancer       Date:  1978-06       Impact factor: 6.860

9.  Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group.

Authors:  J M Bennett; D Catovsky; M T Daniel; G Flandrin; D A Galton; H R Gralnick; C Sultan
Journal:  Br J Haematol       Date:  1976-08       Impact factor: 6.998

10.  Partial deletion of long arm of chromosome 17: a specific abnormality in acute promyelocytic leukemia?

Authors:  H M Golomb; J Rowley; J Vardiman; J Baron; G Locker; S Krasnow
Journal:  Arch Intern Med       Date:  1976-07
View more
  2 in total

1.  Long-term follow-up results of cytarabine-containing chemotherapy for acute promyelocytic leukemia.

Authors:  Young Hoon Park; Dae-Young Kim; Yeung-Chul Mun; Eun Kyung Cho; Jae Hoon Lee; Deog-Yeon Jo; Inho Kim; Sung-Soo Yoon; Seon Yang Park; Byoungkook Kim; Soo-Mee Bang; Hawk Kim; Young Joo Min; Jae Hoo Park; Jong Jin Seo; Hyung Nam Moon; Moon Hee Lee; Chul Soo Kim; Won Sik Lee; So Young Chong; Doyeun Oh; Dae Young Zang; Kyung Hee Lee; Myung Soo Hyun; Heung Sik Kim; Sung-Hyun Kim; Hyukchan Kwon; Hyo Jin Kim; Kyung Tae Park; Sung Hwa Bae; Hun Mo Ryoo; Jung Hye Choi; Myung-Ju Ahn; Hwi-Joong Yoon; Sung-Hyun Nam; Bong-Seog Kim; Chu-Myong Seong
Journal:  Korean J Intern Med       Date:  2022-06-28       Impact factor: 3.165

Review 2.  Upgrade of an old drug: Auranofin in innovative cancer therapies to overcome drug resistance and to increase drug effectiveness.

Authors:  Tania Gamberi; Giovanni Chiappetta; Tania Fiaschi; Alessandra Modesti; Flavia Sorbi; Francesca Magherini
Journal:  Med Res Rev       Date:  2021-12-01       Impact factor: 12.388

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.